Amyris, Inc. (NASDAQ:AMRS) has been assigned an average rating of “Hold” from the six brokerages that are covering the company, reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $30.25.

AMRS has been the subject of several research analyst reports. Zacks Investment Research raised shares of Amyris from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Amyris in a research note on Tuesday, May 23rd. ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Cowen and Company set a $4.00 target price on shares of Amyris and gave the company a “hold” rating in a research note on Thursday, August 17th.

Shares of Amyris (NASDAQ AMRS) opened at 2.76 on Monday. The stock’s 50 day moving average is $2.96 and its 200-day moving average is $5.05. Amyris has a 12-month low of $0.21 and a 12-month high of $18.15. The company’s market capitalization is $103.79 million.

Amyris (NASDAQ:AMRS) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $0.35. The company had revenue of $25.68 million for the quarter, compared to the consensus estimate of $23.68 million. The business’s quarterly revenue was up 167.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.06) earnings per share. Analysts anticipate that Amyris will post ($3.32) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Amyris, Inc. (AMRS) Given Consensus Rating of “Hold” by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at

A hedge fund recently raised its stake in Amyris stock. Bank of New York Mellon Corp boosted its stake in shares of Amyris, Inc. (NASDAQ:AMRS) by 16.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,768 shares of the biotechnology company’s stock after buying an additional 4,603 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.17% of Amyris worth $104,000 as of its most recent SEC filing. 19.79% of the stock is owned by institutional investors and hedge funds.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.